Compare Abeona Therapeutics Inc (ABEO) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Centrus Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Centrus Energy Corp trades at $187 (market cap $3.77B). The key difference: Centrus Energy Corp is far larger — about 9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | LEU | |
|---|---|---|
Market Cap | $421.19M | $3.77B |
Sector | Health | Energy |
52-Week High | $7.45 | $436.00 |
52-Week Low | $4.17 | $146.61 |
Enterprise Value | $276.10M | $3.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Centrus Energy (LEU) trades at $189.03, down 0.16% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 revenue of $176.1 million, beating expectations, but net income declined to $16.8 million from $28.9 million year-over-year due to higher costs. Recent developments include a $900 million DOE contract and a HALEU supply agreement with X-energy, positioning Centrus as a key player in the nuclear fuel supply chain with a $4.5 billion backlog.
The outlook for LEU is positive given its strategic role in nuclear energy expansion and strong institutional support, but risks include margin compression and execution challenges. Analysts maintain a buy consensus with a $228.50 price target, representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
